Notably, combined treatment of GL261 gliomas with a TGF-β neutralizing antibody to reduce immunosuppression and vaccination with glioma-associated antigens resulted in increased tumor-specific, IFN-γ producing CD8+ T cells and improved survival[11]. This evidence concerns the gene TGFB1 and glioma.